Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1374 • ACR Convergence 2024
Exploring Two Decades of Therapeutic Challenges: A Monocentric Experience in Rheumatoid Arthritis Patients Battling Cancer
Roba Ghossan¹, Elodie Portier², OLIVIER FOGEL³, Sophie Hecquet¹, Astrid Dauchez¹, Omar AL TABAA⁴, Marion THOMAS⁵, Julia Herrou¹, Yannick Allanore⁶ and Jérôme Avouac⁷, ¹COCHIN HOSPITAL, PARIS, France, ²Cochin Hospital, Bry sur Marne, France, ³AP-HP, Paris, France, ⁴APHP - Cochin Hospital, Paris, France, ⁵APHP, Paris, France, ⁶Université Paris Cité, Paris, France, ⁷Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Managing inflammatory arthritis patients on biologics with a history of cancer remains a complex task in daily rheumatology practice and requires a thoughtful, individualized…
Abstract Number: 1391 • ACR Convergence 2024
Possible Mechanistic Pathways of the Effective “Plants for Joints” Lifestyle and Dietary Intervention for Rheumatoid Arthritis
Carlijn Wagenaar¹, Márcia Pereira², Sylvio Redanz³, Arne Gessner⁴, Wendy Walrabenstein⁵, Martin Kriegel³, Mario Zaiss⁶ and Dirkjan van Schaardenburg⁷, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²University of Münster, Münster, Germany, ³Institute of Musculoskeletal Medicine, University of Münster, Department of Translational Rheumatology and Immunology, Münster, Germany, Münster, Germany, ⁴Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁵Reade Center for Rheumatology and Rehabilitation, Amsterdam, Netherlands, ⁶Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universittsklinikum Erlangen, Erlangen, Germany; 2 Deutsches Zentrum für Immuntherapie (DZI), Erlangen, Germany, ⁷Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: The 16-week Plants for Joints (PFJ) intervention, consisting of a whole-food plant-based diet, physical activity, and stress management, significantly reduced 28-joint Disease Activity Score…
Abstract Number: 1659 • ACR Convergence 2024
Shared Lung and Joint T Cell Repertoire in Early Rheumatoid Arthritis Driven by Cigarette Smoking
Koen Venken¹, Matthias Jarlborg¹, Frederik Stevenaert², Thomas Malfait³, Carolien Vlieghe¹, Yann Abraham², Teddy Manuello¹, Tine Decruy¹, Stijn Van Hee¹, Hans Wils², Pieter Peeters², Philippe Carron⁴, Filip Van den Bosch³, Viggo Van Tendeloo², Bart Lambrecht¹, Ruth Wittoek⁵, Peggy Jacques⁶ and Dirk Elewaut⁷, ¹VIB Center for Inflammation Research - Ghent University, Ghent, Belgium, ²Janssen Research and Development, Beerse, Belgium, ³Ghent University Hospital, Ghent, Belgium, ⁴UZ Gent, Gent, Belgium, ⁵Dept. of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, ⁶University Hospital of GHent, Gent, Belgium, ⁷Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: Cigarette smoking has been associated with the production of anti-citrullinated protein antibodies (ACPA) and an increased risk of developing rheumatoid arthritis (RA) in individuals…
Abstract Number: 1724 • ACR Convergence 2024
Performance of a Novel Cardiovascular Risk Calculator in Rheumatoid Arthritis
Tate Johnson¹, Halie Frideres², Punyasha Roul³, Yangyuna Yang¹, Joshua Baker⁴, Sauer brian⁵, grant Cannon⁶, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC Department of Rheumatology, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Existing cardiovascular disease (CVD) risk calculators have inadequately estimated CVD risk in people with rheumatoid arthritis (RA). The American Heart Association (AHA) recently developed…
Abstract Number: 1856 • ACR Convergence 2024
Distinct Proliferative and Special Properties of Peripheral Helper T Cells in RA Synovium
Yuki Masuo¹, Akinori Murakami¹, Rinko Akamine¹, Osamu Iri¹, Koichi Murata¹, Kohei Nishitani¹, Hiromu Ito¹, Takayuki Fujii¹, Ryu Watanabe², Takeshi Iwasaki¹, Shinichiro Nakamura¹, Shinichi Kuriyama¹, Yugo Morita¹, Yasuhiro Murakawa¹, Chikashi Terao³, Yukinori Okada⁴, Motomu Hashimoto², Shuichi Matsuda⁵, Hideki Ueno¹ and Hiroyuki Yoshitomi¹, ¹Kyoto University, Kyoto, Japan, ²Osaka Metropolitan University, Osaka, Japan, ³RIKEN, Tokyo, Japan, ⁴The University of Tokyo / Osaka University / RIKEN, Tokyo, Japan, ⁵Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan
Background/Purpose: Tertiary lymphoid structures (TLSs) are organized aggregates of immune cells that are frequently observed in the target tissues of chronic diseases. In patients with…
Abstract Number: 1936 • ACR Convergence 2024
Referral and Diagnostic Delays of Patients with Chronic Inflammatory Rheumatic Diseases: A Cross-sectional Study in Eight Countries
Nelly Ziade¹, Nizar Ani², avin maroof³, ASAL ADNAN RIDHA⁴, Manal El Rakawi⁵, Chafika Haouichat⁵, Bassel Elzorkany⁶, Sherif Gamal⁷, Mariama Erraoui⁸, Manal Al-Mashaleh⁹, Fatima Alnaimat¹⁰, Basel masri¹¹, fatemah Baron¹², Lina El Kibbi¹³, Krystel Aouad¹⁴, Karen Mechleb¹⁵ and Ihsane Hmamouchi¹⁶, and ARCH ArLAR, ¹Saint-Joseph University, Beirut, Lebanon, ²Baghdad College of Medicine, Baghdad, Iraq, ³University of Kurdistan Hawler, Erbil, Iraq, ⁴Baghdad Teaching Hospital, baghdad, Iraq, ⁵Djillali Bounaama University Hospital, Algiers, Algeria, ⁶Private (BZRC), Cairo, Egypt, ⁷Cairo University, Cairo, Egypt, ⁸Souss Massa Univeristy, Rabat, Morocco, ⁹Royal Medical Services, Amman, Jordan, ¹⁰The University of Jordan, amman, Jordan, ¹¹Jordan Hospital and Medical Center, Amman, Jordan, ¹²Al-Jahra Hospital, Ministry of Health, Kuwait, Kuwait, ¹³Specialized Medical Center, Riyadh, Saudi Arabia, ¹⁴Saint George Hospital University Medical Center, Beirut, Lebanon, ¹⁵Saint Joseph University Beirut, Beirut, Lebanon, ¹⁶Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco
Background/Purpose: Patients with chronic inflammatory rheumatic diseases (CIRDs) may benefit from a critical window of opportunity for early intervention, yet referral delays remain a major…
Abstract Number: 2141 • ACR Convergence 2024
Glucocorticoid Therapy-Associated Bone Fractures Are Associated with Osteoporosis Underscreening in Patients with Rheumatoid Arthritis
Marlene Marte Furment¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY
Background/Purpose: The majority of bone loss happens within 6 months of glucocorticoid treatment. Per the 2022 American College of Rheumatology (ACR) Glucocorticoid-Induced Osteoporosis Guidelines it…
Abstract Number: 2222 • ACR Convergence 2024
Primary Lung Involvement in Early Rheumatoid Arthritis
Martí Aguilar Coll¹, Javier Narvaez-García², Alejandro Robles Pérez¹, Patricio Luburich¹, Vanesa Vicens-Zygmunt³, Gualadalupe Bermudo³, Santiago Bolivar¹, Pol Maymó³, Judith Palacios¹, Monserrat Roig Kim², Laia De Daniel², Maria Molina-Molina³ and Joan Miquel Nolla¹, ¹Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitario de Bellvitge., Barcelona, Spain
Background/Purpose: Since there is broad variability within the studies investigating this issue, it is not possible nowadays to reliably establish prevalence and incidence of rheumatoid…
Abstract Number: 2238 • ACR Convergence 2024
The Effect of Inflammation on Cardiovascular Risk in Rheumatoid Arthritis Varies According to Sex and Anticitrullinated Protein Antibody Status
George Karpouzas¹, Piet Van RIel², Elena Myasoedova³, Miguel Angel Gonzalez-Gay⁴, alfonso Corrales-Martínez⁵, Solbritt Rantapaa-Dahlqvist⁶, Petros Sfikakis⁷, Patrick Dessein⁸, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawy¹¹, Virginia Pascual Ramos¹², Irazu Contreras Yanez¹³, Iris Jazmín Colunga Pedraza¹⁴, Dionicio Galarza-Delgado¹⁵, jose Ramon Azpiri-Lopez¹⁶, Anne Grete Semb¹⁷, Durga P Misra¹⁸, Patrick Durez¹⁹, Brian Bridal Logstrup²⁰, Ellen Margrethe Hauge²¹, George Kitas²² and Sarah Ormseth²³, and ATACC-RA, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Radboud University Medical Center, Nijmegen, Netherlands, ³Mayo Clinic, Rochester, MN, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁶Umeå University, Umeå, Sweden, ⁷Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁸University of Witwatersrand, Johannesburg, South Africa, ⁹University of Witwatersrand, Johanessburg, South Africa, ¹⁰University of Mannitoba, Winnipeg, Canada, ¹¹University of Mannitoba, Winnipeg, MB, Canada, ¹²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ¹³Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁵UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ¹⁶Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁷Diakonhjemmet Hospital, Oslo, Norway, ¹⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁹UCLouvain, Louvain, Belgium, ²⁰University of Aarhus, Aarhus, Denmark, ²¹Aarhus Universitetshospital, Aarhus, Denmark, ²²The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, ²³The Lundquist Institute, Torrance, CA
Background/Purpose: Disease activity associated with cardiovascular (CV) risk in rheumatoid arthritis (RA). Females with RA exhibit higher disease activity than males. Yet, males with RA…
Abstract Number: 2257 • ACR Convergence 2024
Comparison of the Safety and Effectiveness of Originator Rituximab (Mabthera®) versus Biosimilar (Riximyo®) in Rheumatoid Arthritis: A Retrospective Unicentric Analysis
Barbara Bayeh¹, Fanny Neira¹, Karina Bonfiglioli¹, Nadia Aikawa², ANA PAULA ASSAD¹, Renata Miossi¹, Fernando Souza³, Carlos Emilio Insfran Echauri¹, Henrique Giardini¹, Emily Figueiredo Neves Yuki¹, Henrique Carriço Da Silva¹, Andre Franco¹, Diogo Domiciano¹, Julio Moraes⁴, Eloisa Bonfa¹, Carla Goncalves Schahin Saad³, Ana Cristina Medeiros-Ribeiro⁵ and Andrea Shimabuco³, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil
Background/Purpose: Immunobiological drugs emerged as a revolutionary option for treating inflammatory chronic rheumatic diseases, particularly rheumatoid arthritis (RA). However, the extremely high costs associated with…
Abstract Number: 2276 • ACR Convergence 2024
Use of Methotrexate and TNF-α Inhibitors in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease: A Survey of Rheumatologists
Elizabeth Park¹, Rabia Iqbal², Elana Bernstein³ and Jon Giles⁴, ¹Columbia University Medical Center, New York, NY, ²Columbia University Irving Medical Center, Brooklyn, NY, ³Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ⁴Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) is among the most common extra-articular manifestations of RA, with symptomatic disease prevalent in approximately 10% of patients.1 Patients with…
Abstract Number: 2539 • ACR Convergence 2024
Telocytes Integrated into Mast Cells and Joint-Draining Lymphatic Vessels Potentially Regulate Lymphatic Clearance
Yue Peng¹, H. Mark Kenney², Karen Bentley¹, Lianping Xing³, Benjamin Korman⁴, Christopher Ritchlin⁵ and Edward Schwarz¹, ¹University of Rochester School of Medicine and Dentistry, Rochester, NY, ²University of Rochester School of Medicine and Dentistry, Henrietta, NY, ³University of Rochester School of Medicine and Dentistry, Webster, NY, ⁴University of Rochester, Rochester, NY, ⁵Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY
Background/Purpose: Rheumatoid arthritis (RA) patients and TNF-transgenic mice have lymphatic dysfunction (1). Recently, we showed mast cells involvement, as genetic ablation and drug inhibition decreased…
Abstract Number: 2636 • ACR Convergence 2024
Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA)
Stephen Pennington¹, Ruoyi Zhou², Jonathan Brady², Bruna Wundervald², Andrew Parnell³, Ciarán Duffy², Robert Perryman², James Waddington⁴, Neil McHugh⁵, Deepak Jadon⁶, David Simon⁷, Filippo Fagni⁸, Georg Schett⁹, Fraser Morton¹⁰, Aurelie Najm¹⁰, Stefan Siebert¹¹, Laura Coates¹² and Oliver FitzGerald¹³, ¹UCD, Dublin, Dublin, Ireland, ²Atturos, DUBLIN, Dublin, Ireland, ³NUIM, Maynooth, Ireland, ⁴Agilent, Manchester, United Kingdom, ⁵University of Bath, Bath, United Kingdom, ⁶Cambridge University, Cambridge, United Kingdom, ⁷Charité - Universittsmedizin Berlin, Berlin, Germany, ⁸Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ¹²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ¹³UCD, Dublin 6, Dublin, Ireland
Background/Purpose: In a previous study, we reported the discovery and evaluation of a serum protein (22 peptide) signature (RAPsA Dx) which, when using random forest machine…
Abstract Number: L08 • ACR Convergence 2023
Early Clinical Development of CIT-013, a First in Class NETosis Inhibitor, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers Demonstrating Potent Inhibition of LPS Induced Neutrophil Extracellular Trap Formation
Leonie Middelink¹, Renato Chirivi², Helmuth van Es², Eric Meldrum², Peter van Zandvoort², Tirza Bruurmijn², Matthijs Moerland³ and Patrick Round², ¹Middelinc., Utrecht, Netherlands, ²Citryll BV, Oss, Netherlands, ³CHDR, Leiden, Netherlands
Background/Purpose: Aberrant Neutrophil Extracellular Traps (NETs) production contributes to the pathophysiology of multiple inflammatory and autoimmune diseases such as Rheumatoid arthritis (RA) Hidradenitis suppurativa (HS),…
Abstract Number: L09 • ACR Convergence 2023
Efficacy and Safety of LNK01001 in Chinese Patients with Moderate to Severe Active Rheumatoid Arthritis with an Inadequate Response to Conventional Synthetic DMARDs: 24-week Results from a Phase 2 Trial
Chanyuan Wu¹, Xuebin Wang², Jiankang Hu³, Xiaofei Shi⁴, Xiaoxia Wang⁵, Xuan Zhang⁶, Ju Liu⁷, Hui Rao⁸, Jianhong Zhao⁹, Rong Du¹⁰, Zhenyu Jiang¹¹, Huaxiang liu¹², Lin Liu¹³, Shengyun Liu¹⁴, Changhao Xie¹⁵, Xiangping Liao¹⁶, Lie Dai¹⁷, Zhiduo Hou¹⁸, Jingchun Jin¹⁹, Tianwang Li²⁰, Deqian Meng²¹, Yongfu Wang²², Jian Wu²³, Jieruo Gu²⁴, Wei Wei²⁵, Yu Zhuang²⁶, Kuanting Wang²⁷, Rong Zhang²⁸, Xiao Zhang²⁹, Huaping Wei³⁰, Zhao-Kui Wan³¹, Jun Wang³¹, Michael Vazquez³², Henry Wu³³ and Xiaofeng Zeng¹, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ²Binzhou Medical University Hospital, Binzhou, China, ³Pingxiang People's Hospital, Pingxiang, China, ⁴The 1st Affiliated Hospital of He'nan University, Luoyang, China, ⁵Second Hospital of Shanxi Medical University, Taiyuan, China, ⁶Beijing Hospital, Beijing, China, ⁷Jiujiang No. 1 People's Hospital, Jiujiang, China, ⁸Hunan Provincial People's Hospital, Changsha, China, ⁹Jining First People's Hospital, Jining, China, ¹⁰Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ¹¹First Affiliated Hospital of Jilin University, Changchun, China, ¹²Qilu Hospital of Shandong University, Jinan, China, ¹³Central Hospital of Xuzhou City, Xuzhou, China, ¹⁴The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, ¹⁵The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹⁶Chenzhou First People's Hospital, Binzhou, China, ¹⁷Sun Yat-Sen Memorial Hospital, Guangzhou, China, ¹⁸Shantou University Medical College No.1 Affiliated Hospital, Shantou, China, ¹⁹Yanbian University Affiliated Hospital, Yanbian, China, ²⁰guangdong second provincial general hospital, Guangzhou, China, ²¹Huai'an First People's Hospital, Huaian, China, ²²The First Affiliated Hospital of Baotou Medical College, Baotou, China, ²³The First Affiliated Hospital of Soochow University, Suzhou, China, ²⁴The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²⁵Tianjin Medical University General Hospital, Tianjin, China, ²⁶Huizhou Central People's Hospital, Huizhou, China, ²⁷Peking University Shougang Hospital, Beijing, China, ²⁸The First Hospital of China Medial University, Shenyang, China, ²⁹Guangdong Provincial People's Hospital, Guangzhou, China, ³⁰Lynk Pharmaceuticals Co., Ltd., Hangzhou, China, ³¹Lynk Pharma, Hangzhou, China, ³²Lynk Pharma, Saint Louis, MO, ³³Lynk Pharma, Nanjing, China
Background/Purpose: LNK01001 is a selective oral JAK1 inhibitor in clinical development for treating autoimmune and inflammatory diseases, including rheumatoid arthritis (RA). Here, we report the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].